Mpox vaccine upgrade: new manufacturing method tested in 970 adults

NCT ID NCT07199569

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 31 times

Summary

This study tests whether the MVA-BN mpox vaccine works just as well when made in a different type of cell. About 970 healthy adults aged 18 to 49 will receive two doses. Researchers will compare immune responses and side effects between the standard and new production methods.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONKEYPOX (MPOX) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Accellacare - Knoxville

    Knoxville, Tennessee, 37938, United States

  • Accellacare Research of Salisbury

    Salisbury, North Carolina, 28144, United States

  • Accellacare and McFarland Clinic

    Ames, Iowa, 50010, United States

  • Accellacare of Cary - Cary Medical Group

    Cary, North Carolina, 27518, United States

  • Accellacare of Charleston

    Mt. Pleasant, South Carolina, 29464, United States

  • Avacare

    Austin, Texas, 78705, United States

  • Avacare

    Fort Worth, Texas, 76135, United States

  • Johnson County ClinTrials, LLC

    Lenexa, Kansas, 66219, United States

  • Rochester Clinical Research, Inc

    Rochester, New York, 14609, United States

  • Velocity Clinical Research

    Suffolk, Virginia, 23435, United States

Conditions

Explore the condition pages connected to this study.